| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089471 | GENUS | Formulation of indomethacin |
Apr, 2030
(5 years from now) | |
| US8734847 | GENUS | Formulation of indomethacin |
Apr, 2030
(5 years from now) | |
| US8992982 | GENUS | Formulation of indomethacin |
Apr, 2030
(5 years from now) | |
Tivorbex is owned by Genus.
Tivorbex contains Indomethacin.
Tivorbex has a total of 3 drug patents out of which 0 drug patents have expired.
Tivorbex was authorised for market use on 24 February, 2014.
Tivorbex is available in capsule;oral dosage forms.
Tivorbex can be used as treatment of pain.
The generics of Tivorbex are possible to be released after 23 April, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 24, 2017 |
Drugs and Companies using INDOMETHACIN ingredient
Market Authorisation Date: 24 February, 2014
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL
More Information on Dosage
TIVORBEX family patents
